Drug Profile
Research programme: small molecule therapeutics - Boehringer Ingelheim/HitGen
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator HitGen
- Developer Boehringer Ingelheim; HitGen
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified